QINGDAO, CHINA — QIANMIAO PEPTIDE announced a major expansion of its GMP peptide manufacturing capabilities, increasing production capacity for custom synthesis, catalog peptides, and clinical-grade products. The upgrade strengthens purity control, batch traceability, and delivery reliability for global laboratories and distributors.
Overview
The expansion focuses on GMP compliance, automated synthesis platforms, and advanced analytical capabilities. This investment supports the growing demand from pharmaceutical companies developing peptide-based therapeutics, diagnostics manufacturers, and academic research institutions.
What’s New
Ten new automated peptide synthesizers for high-throughput production.
Expanded HPLC purification capacity with preparative systems and advanced LC-MS/MS equipment.
More synthesis options including non-standard amino acids, post-translational modifications, and complex cyclizations.
Why It Matters
For peptide therapeutics and diagnostic applications, consistent quality and full documentation are critical. QIANMIAO PEPTIDES’s quality systems ensure consistent sequence accuracy, reliable purity, and reproducible results—batch after batch.
Pharmaceutical partners benefit from comprehensive support: regulatory documentation, stability data, and custom packaging solutions.
Availability & Support
For catalog peptides, samples and lead time are available upon request. For custom sequences, feasibility and timeline depend on complexity and quantity.
To discuss your project or request a quote, contact our team with your sequence, target application, and quality requirements.
Contact
Email: info@qmpeptide.com | Phone/WhatsApp: +852 4487 8452
Address: Qingdao, Shandong, China
